The global molecular cytogenetics market accumulated $1.8 billion revenue in 2017, and it is projected to attain a CAGR of 9.9% during the forecast period (2018–2023). The increasing popularity of pharmacogenomics in drug development and personalized disease management, advancements in cytogenetic techniques, and employment of these techniques in detecting chromosomal abnormalities are influencing the market growth. With the growing number of cytogenetic abnormalities, cases of cancer, and drugs becoming redundant in the treatment of diseases, a more robust technique is needed for determining the cause of and managing such conditions.
Molecular cytogenetics is the branch of genetics that deals with the study of chromosomal structure, its location and function within a cell, and the detection of genetic diseases. It utilizes techniques such as comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and karyotyping in various applications of biology and medicine. The market is segmented by technology, application, end-user, geography, and offering. On the basis of technology, the market is subdivided into FISH, IHC, CGH, karyotyping, and others. The market for FISH is expected to grow at a CAGR of 10.1% during the forecast period.
 |
| Request for sample Copy of this Report: http://bit.ly/2PbFbmi |
The CGH subdivision is further classified into standard CGH and array-based CGH, of which array-based CGH held 55.4% share in the molecular cytogenetics market in 2017. In the application segment, the market has genetic disorders, cancer, and personalized medicine as its categories. In 2017, cancer was the largest application of molecular cytogenetics, accumulating a market share of 41.9%. This is credited to the increasing prevalence of cancer and the growing focus of research groups on developing diagnostic tools for it and other genetic disorders.
The global molecular cytogenetics market is being driven by a number of factors, one being the rising cases of cancer. Cancer as a disease involves numerous mutations, which are either disease-specific or could vary from one individual to another. Molecular cytogenetics techniques such as single nucleotide polymorphism (SNP), CGH, FISH, and genomic expression profiling are not only helping researchers in identifying cancer-specific biomarkers, but are also helping doctors in providing better diagnosis, prognosis and treatment to patients.
Secondly, the advancements in molecular cytogenetic techniques have revolutionized the field of diagnostics. The automation of the cytogenetic analysis process has played a major role in the development of molecular cytogenetics by reducing manual involvement and increasing cost and time-effectiveness. Reduced manual handling of such processes has minimized the risk of errors, thus providing accurate results. It is further predicted to present the possibility of widening the range of molecular cytogenetic testing, hence increase the scope of the molecular cytogenetics market during the forecast period.
Thus, the market is set to grow during the forecast period owing to the advancements in technology in the field of biology and medicine.
